Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Conference Call March 27, 2024 8:30 AM ET

Company Participants

Karen Hunady - Director of IR and Corporate Communications
Conley Chee - CEO
David Roth - CMO
Jason Haas - CFO

Conference Call Participants

Phil Nadeau - TD Cowen
Jason Butler - Citizens JMP

Operator

Good morning and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded.

At this time, I would like to turn the call over to Karen Hunady, Director of Investor Relations and Corporate Communications at Syros.

Karen Hunady

Thank you. This morning, we issued a press release announcing our fourth quarter and full year 2023 financial results. The full release is available on the Investor & Media section of the Syros' website at www.syros.com.

We will begin the call with prepared remarks by Conley Chee, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Kristin Stephens, our Chief Development Officer, is also here on the call and will be available for Q&A.

Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed, or implied by any forward-looking statement as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section, of our annual report on Form 10-K that we filed this morning and any other filings that we may make with the SEC in the future.

Any forward-looking statements, represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.

With that, I would now like to turn the call over to Conley. Conley?

Conley Chee

Thank you, Karen. Good morning, everyone, and thank you for joining us.

Late last year, we announced the initial data from our SELECT-AML-1 trial, and since then, we've continued to make great progress in our effort to become a commercial-stage biotech company. Following our initial AML data, we completed an equity financing of approximately $45 million, reinforcing our cash position, and providing us ample resources as we enter into 2024.